Safety and immunogenicity of an HIV-1 tat toxoid vaccine in HIV-1 infected volunteers on highly active anti retroviral therapy (HAART)

被引：0
|
作者：
Frachette, MJ [1 ]
机构：
[1] Aventis Pasteur, F-69280 Marcy Letoile, France
来源：
RETROVIRUSES OF HUMAN AIDS AND RELATED ANIMAL DISEASES | 2003年
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：179 / 181
页数：3
相关论文
共 50 条
  • [1] Changes in immune parameters in HIV-1 infected children during highly active anti-retroviral therapy (HAART).
    Westby, M
    Watkins, AM
    Drake, J
    Wills, B
    Cammack, N
    Sharland, M
    AIDS, 1998, 12 : S95 - S95
  • [2] Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1 infected women
    Johnson, DC
    McFarland, EJ
    Muresan, P
    Fenton, T
    McNamara, J
    Read, JS
    Hawkins, E
    Bouquin, PL
    Estep, SG
    Tomaras, GD
    Vincent, CA
    Rathore, M
    Melvin, AJ
    Gurunathan, S
    Lambert, J
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (12): : 2129 - 2133
  • [3] Immunogenicity and Efficacy of a Therapeutic HIV-1 Vaccine (HIVAX™) in HIV Patients on HAART
    Tung, F.
    Tung, J. K.
    Castro, J.
    Boliva, H.
    Fischl, M. A.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (11) : A173 - A173
  • [4] TheraVac-01: Evaluation of Safety and Immunogenicity of the HIV-1 Vaccine NYVAC-B in Chronic HIV-1 Infected Patients Successfully Treated with HAART
    Bart, P-A
    Harari, A.
    Vermeulen, J. N.
    Enders, F. Bellutti
    Bataenjer, E. Castro
    Cavassini, M.
    Wit, F. W.
    Autran, B.
    Lange, J. M.
    Pantaleo, G.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 : 149 - 149
  • [5] Arresting HIV-1 evolution with highly active antiretroviral therapy (HAART)
    Persaud, D
    Hermankova, M
    Ruff, C
    Ray, SC
    Siliciano, RF
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1221 - 1221
  • [6] Multicenter study of safety and immunogenicity of HIV-1 rgp160 candidate vaccine in seropositive HIV-1 volunteers.
    Goebel, FD
    Mannhalter, JW
    Eibl, MM
    Belshe, RB
    Grob, P
    Erfle, V
    Griffiths, PD
    Wahren, B
    Krohn, K
    Kunschak, M
    Engl, W
    AIDS, 1996, 10 : OP64 - OP64
  • [7] Prospective study of immune responses to tetanus toxoid booster in HIV-1 infected children and adolescents on highly active antiretroviral therapy (HAART)
    Ching, N
    Deville, J
    Nielsen, K
    Ank, B
    Wei, LS
    Glenn, SC
    Wolinsky, S
    Bryson, YJ
    PEDIATRIC RESEARCH, 2004, 55 (04) : 328A - 328A
  • [8] The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART
    Peng, Jinsong
    Vigorito, Michael
    Liu, Xiangqian
    Zhou, Dunjing
    Wu, Xiongwen
    Chang, Sulie L.
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 218 (1-2) : 94 - 101
  • [9] ASSESSMENT OF CYTOKINE VALUES IN SERUM BY RT-PCR IN HIV-1 INFECTED INDIVIDUALS WITH AND WITHOUT HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY (HAART)
    Meira, D. A.
    Almeida, R. A. M. B.
    Barbosa, A. N.
    de Souza, L. R.
    Olivo, T. E. T.
    Henriques, R. M. S.
    Golim, M. A.
    Araujo Jr, J. P.
    Nagoshi, L. R.
    Orikaza, C. M.
    Calvi, S. A.
    JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES, 2008, 14 (04): : 685 - 702
  • [10] Impact of highly active antiretroviral therapy (HAART) on clinical outcomes of vertically HIV-1 infected children
    Claudia Palladino
    Jose María Bellón
    Laura Díaz Muñoz
    Dolores Garcia Alonso
    MªÁngeles Muñoz-Fernandez
    Retrovirology, 5 (Suppl 1)
12345